Where some of your focus should be campers....
Agreement with leading laboratory supplier MIKRO + POLO D.O.O. (Mikro+Polo) making it the sole and exclusive provider with the right to sell, market and distribute upcoming MGC Pharmaceutical branded cannabis APIs to all new Mikro+Polo government tender customers across Slovenia, Croatia and Bosnia.
Under the agreement, the cannabis API (a substance or combination of substances used in a finished pharmaceutical product for the purposes of medical treatment or clinical trials) will be supplied to Mikro+Polo at an agreed price based on the underlying market price for Phytocannabinoids API, which is currently over €60/gram.
https://www.asx.com.au/asxpdf/20170619/pdf/43k0qcxptyx0ns.pdfThe Company will supply four of its cannabinoids rich medicinal
cannabis flower products (MX201, MX21, MX11 and MX120) to Lenis for wholesale distribution into countries including Latvia, Lithuania, Estonia, Slovenia, Croatia, Bosnia and Herzegovina, Serbia, Macedonia, Hungary, Romania, Bulgaria and Poland at an agreed wholesale price. Furthermore, MGC and Lenis will jointly market the products into Germany, Croatia, Greece and Italy.
The flower products will be available in pharmacies for the treatment or relief of symptoms for a variety of medical conditions, such as nausea, vomiting, pain, Tourette's syndrome, multiple sclerosis, uncontrollable severe epilepsy, inflammatory bowel disease, Crohn's For personal use only disease, ulcerative colitis and post-traumatic stress disorder.
https://www.asx.com.au/asxpdf/20171003/pdf/43mwyt2nty4zr4.pdfpermission to operate its Phytocannabinoid extraction at its Manufacturing Facility in Ljubljana, for the purposes of;
1. Development of new formulations with Phytocannabinoids coming from different genetics to gain different and new natural API
2. Development of own Phytocannabinoids (THC, CBD, etc.) active ingredient API (Active Pharmaceutical Ingredient) from cannabis plants
3. Optimize and validation of the extraction and isolation process with the purpose of control and understanding of all components
company can now produce its API’s in house at a very low cost base for its own Phytomedicine production
https://www.asx.com.au/asxpdf/20190122/pdf/4420dy8rnq440s.pdf
